LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 251

Search options

  1. Article ; Online: Severe symptomatic late onset dermographism after mRNA COVID-19 vaccine.

    Patruno, Cataldo / Fabbrocini, Gabriella / Napolitano, Maddalena

    Italian journal of dermatology and venereology

    2024  Volume 159, Issue 1, Page(s) 60–61

    MeSH term(s) Humans ; Chronic Inducible Urticaria ; COVID-19/prevention & control ; COVID-19 Vaccines/adverse effects ; RNA, Messenger ; Urticaria
    Chemical Substances COVID-19 Vaccines ; RNA, Messenger
    Language English
    Publishing date 2024-01-23
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 3065415-4
    ISSN 2784-8450
    ISSN (online) 2784-8450
    DOI 10.23736/S2784-8671.23.07454-6
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 119: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Considerations for managing elderly patients with atopic dermatitis.

    Napolitano, Maddalena / Potestio, Luca / Nocerino, Mariateresa / Patruno, Cataldo

    Expert review of clinical immunology

    2024  Volume 20, Issue 5, Page(s) 501–511

    Abstract: Introduction: Atopic dermatitis (AD) diagnosis in elderly is challenging, due to its clinical polymorphism and the lack of diagnostic biomarkers. Moreover, the chronicity of the disease and the complex pathogenetic mechanism, make elderly AD management ... ...

    Abstract Introduction: Atopic dermatitis (AD) diagnosis in elderly is challenging, due to its clinical polymorphism and the lack of diagnostic biomarkers. Moreover, the chronicity of the disease and the complex pathogenetic mechanism, make elderly AD management challenging.
    Areas covered: A narrative review of the current literature was performed using the PubMed, Medline, Embase, and Cochrane Skin databases, by researching the following terms: 'atopic dermatitis,' 'clinical phenotypes,' 'eczema,' 'elderly patients,' 'elderly type atopic dermatitis,' 'eczema clinical presentation.' The aim was to report the current knowledge on pathogenesis, clinical presentation, and treatment options of elderly AD.
    Expert opinion: Elderly type AD has recently been identified as a separate entity, with an increasing prevalence. With aging, both immunosenescence and barrier alterations can cause or modify AD presentation. Moreover, a chronic proinflammatory state (so-called 'inflammaging') is often present in elderly subjects. Older patients with AD may present with peculiar immunophenotypic profile, making AD diagnosis challenging. Similarly, the chronicity of the disease and the complex pathogenetic mechanism, make AD management a challenge. Indeed, systemic therapies for AD are often contraindicated or not tolerated and the management of elderly type AD is often burdened with numerous difficulties, leading to undertreated disease. Even if dupilumab and tralokinumab represent a valuable therapeutic weapon, more data on safety of JAK inhibitors are required.
    MeSH term(s) Humans ; Aged ; Dermatitis, Atopic/therapy ; Dermatitis, Atopic/drug therapy ; Skin/pathology ; Eczema/epidemiology
    Language English
    Publishing date 2024-01-09
    Publishing country England
    Document type Journal Article ; Review
    ZDB-ID 2274260-8
    ISSN 1744-8409 ; 1744-666X
    ISSN (online) 1744-8409
    ISSN 1744-666X
    DOI 10.1080/1744666X.2024.2301967
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6661: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Injection site reactions after dupilumab or tralokinumab for atopic dermatitis.

    Martora, Fabrizio / Patruno, Cataldo / D'Ascenzo, Silvia / Napolitano, Maddalena

    The Journal of dermatological treatment

    2024  Volume 35, Issue 1, Page(s) 2304027

    Abstract: Background: ...

    Abstract Background:
    MeSH term(s) Adult ; Humans ; Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal, Humanized/adverse effects ; Dermatitis, Atopic/complications ; Double-Blind Method ; Injection Site Reaction/etiology ; Injection Site Reaction/epidemiology ; Severity of Illness Index ; Treatment Outcome
    Chemical Substances Antibodies, Monoclonal ; Antibodies, Monoclonal, Humanized ; dupilumab (420K487FSG) ; tralokinumab (GK1LYB375A)
    Language English
    Publishing date 2024-01-19
    Publishing country England
    Document type Journal Article ; Observational Study
    ZDB-ID 1036299-x
    ISSN 1471-1753 ; 0954-6634
    ISSN (online) 1471-1753
    ISSN 0954-6634
    DOI 10.1080/09546634.2024.2304027
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 2627: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: Kaposi's sarcoma as presentation of HIV in an atopic patient treated with upadacitinib.

    Potestio, Luca / Patruno, Cataldo / Genco, Lucia / DI Filippo, Giovanni / Napolitano, Maddalena

    Italian journal of dermatology and venereology

    2024  Volume 159, Issue 2, Page(s) 211–212

    Language English
    Publishing date 2024-04-23
    Publishing country Italy
    Document type Journal Article
    ZDB-ID 3065415-4
    ISSN 2784-8450
    ISSN (online) 2784-8450
    DOI 10.23736/S2784-8671.24.07766-1
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 119: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Efficacy and Safety of Tralokinumab in Real Life: Possible Predictive Rapid Response Factors.

    Potestio, Luca / Patruno, Cataldo / Napolitano, Maddalena

    Dermatitis : contact, atopic, occupational, drug

    2023  Volume 35, Issue S1, Page(s) S77–S80

    MeSH term(s) Humans ; Retrospective Studies ; Dermatitis, Atopic/drug therapy ; Pruritus/chemically induced ; Pruritus/drug therapy ; Immunoglobulin A ; Treatment Outcome ; Severity of Illness Index ; Double-Blind Method ; Antibodies, Monoclonal
    Chemical Substances tralokinumab (GK1LYB375A) ; Immunoglobulin A ; Antibodies, Monoclonal
    Language English
    Publishing date 2023-11-14
    Publishing country United States
    Document type Journal Article
    ZDB-ID 2144723-8
    ISSN 2162-5220 ; 1532-8163 ; 1710-3568
    ISSN (online) 2162-5220 ; 1532-8163
    ISSN 1710-3568
    DOI 10.1089/derm.2023.0261
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3680: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: The Risk of Herpes Virus Infection in Patients With Atopic Dermatitis During Biologic Therapy: A Retrospective Records Based Observational Study.

    Napolitano, Maddalena / Torta, Ginevra / Potestio, Luca / Patruno, Cataldo

    Dermatitis : contact, atopic, occupational, drug

    2023  Volume 35, Issue S1, Page(s) S105–S106

    MeSH term(s) Humans ; Dermatitis, Atopic/drug therapy ; Retrospective Studies ; Biological Therapy ; Virus Diseases
    Language English
    Publishing date 2023-11-27
    Publishing country United States
    Document type Observational Study ; Letter
    ZDB-ID 2144723-8
    ISSN 2162-5220 ; 1532-8163 ; 1710-3568
    ISSN (online) 2162-5220 ; 1532-8163
    ISSN 1710-3568
    DOI 10.1089/derm.2023.0160
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3680: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article: Vitiligo during dupilumab therapy.

    Picone, Vincenzo / Napolitano, Maddalena / Torta, Ginevra / Fabbrocini, Gabriella / Patruno, Cataldo

    JAAD case reports

    2023  Volume 36, Page(s) 51–53

    Language English
    Publishing date 2023-04-26
    Publishing country United States
    Document type Case Reports
    ZDB-ID 2834220-3
    ISSN 2352-5126
    ISSN 2352-5126
    DOI 10.1016/j.jdcr.2023.03.025
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: Dupilumab-associated inflammatory arthritis: a literature review.

    Napolitano, Maddalena / Ruggiero, Angelo / Patruno, Cataldo

    Clinical and experimental dermatology

    2023  Volume 49, Issue 4, Page(s) 307–312

    Abstract: Dupilumab is a fully human monoclonal antibody that acts by inhibiting the interleukin (IL)-4 receptor subunit α, and hence the IL-4 and IL-13 signalling pathway. Dupilumab treatment has been linked to the onset of T helper 17-driven inflammatory ... ...

    Abstract Dupilumab is a fully human monoclonal antibody that acts by inhibiting the interleukin (IL)-4 receptor subunit α, and hence the IL-4 and IL-13 signalling pathway. Dupilumab treatment has been linked to the onset of T helper 17-driven inflammatory diseases, including cases of seronegative arthritis and enthesitis. To date, dupilumab-associated inflammatory arthritis (DAIA) represents a relatively unknown adverse event, initially reported in single cases or case series reports. Indeed, the onset of DAIA may not be promptly recognized, and is probably underestimated. Here we have reviewed the available English literature regarding arthritis and enthesitis onset during dupilumab treatment for atopic dermatitis, aiming to improve rapid recognition and thus prompt treatment of these diseases.
    MeSH term(s) Humans ; Antibodies, Monoclonal, Humanized/adverse effects ; Antibodies, Monoclonal/adverse effects ; Dermatitis, Atopic ; Interleukin-13
    Chemical Substances dupilumab (420K487FSG) ; Antibodies, Monoclonal, Humanized ; Antibodies, Monoclonal ; Interleukin-13
    Language English
    Publishing date 2023-11-27
    Publishing country England
    Document type Review ; Journal Article
    ZDB-ID 195504-4
    ISSN 1365-2230 ; 0307-6938
    ISSN (online) 1365-2230
    ISSN 0307-6938
    DOI 10.1093/ced/llad390
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 1278: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article ; Online: An overview of new and emerging antibody therapies for moderate-severe atopic dermatitis in adults.

    Picone, Vincenzo / Vallone, Ylenia / Patruno, Cataldo / Napolitano, Maddelena

    Expert review of clinical pharmacology

    2023  Volume 16, Issue 12, Page(s) 1239–1248

    Abstract: Introduction: A comprehensive review of the English-language medical literature was performed searching for ongoing and closed clinical trials concerning new and emerging monoclonal antibody therapies for moderate-to-severe atopic dermatitis in adults.!# ...

    Abstract Introduction: A comprehensive review of the English-language medical literature was performed searching for ongoing and closed clinical trials concerning new and emerging monoclonal antibody therapies for moderate-to-severe atopic dermatitis in adults.
    Areas covered: Atopic dermatitis is a chronic inflammatory cutaneous disease with a complex pathogenesis. In the last years, numerous advances in understanding the atopic dermatitis pathogenesis allowed to obtain several therapeutic options, such as numerous monoclonal antibodies. Some monoclonal antibodies, such as dupilumab (anti-IL-4 Rα) and tralokinumab (anti-IL13) are already approved for the treatment of moderate-to-severe atopic dermatitis, and numerous articles in the literature have demonstrated their efficacy and safety. As there are numerous drugs under investigation, this review focuses on emerging monoclonal antibody therapies.
    Expert opinion: There are numerous monoclonal antibodies under investigation that may be approved in the near future for the treatment of atopic dermatitis. Data from phase 2b and phase III clinical trials in moderate-to-severe atopic dermatitis in adults indicate that these drugs have a promising efficacy and safety profile. Monoclonal antibodies currently under investigation will be available in the coming years to enrich the therapeutic choice of new alternatives that are valid both in terms of efficacy and safety.
    MeSH term(s) Adult ; Humans ; Dermatitis, Atopic/pathology ; Antibodies, Monoclonal/adverse effects ; Administration, Cutaneous ; Treatment Outcome ; Severity of Illness Index
    Chemical Substances Antibodies, Monoclonal
    Language English
    Publishing date 2023-12-09
    Publishing country England
    Document type Journal Article ; Review
    ISSN 1751-2441
    ISSN (online) 1751-2441
    DOI 10.1080/17512433.2023.2292615
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  10. Article ; Online: Dupilumab-associated cutaneous adverse events among adult patients with atopic dermatitis: A retrospective study.

    Napolitano, Maddalena / Fabbrocini, Gabriella / Patruno, Cataldo

    The Journal of dermatology

    2023  Volume 50, Issue 7, Page(s) 880–887

    Abstract: Dupilumab, a monoclonal antibody inhibiting interleukin (IL) 4 and IL-13, is approved for the treatment of moderate to severe atopic dermatitis (AD) in children aged ≥6 years, adolescents, and adults. Both clinical trials and real-life data demonstrate ... ...

    Abstract Dupilumab, a monoclonal antibody inhibiting interleukin (IL) 4 and IL-13, is approved for the treatment of moderate to severe atopic dermatitis (AD) in children aged ≥6 years, adolescents, and adults. Both clinical trials and real-life data demonstrate its efficacy and safety. However, some cutaneous adverse events (cAEs) have been observed during real-world experiences. The authors' aim was to analyze the spectrum of cAEs in patients receiving dupilumab for the treatment of AD in a real-world setting. A retrospective review of electronic medical records was conducted for 916 patients (475 males and 541 females; mean age, 50.23 ± 19.66 years [range, 18-91 years]) who had received dupilumab for a minimum of 1 month for the treatment of AD from December 2018 to November 2022 at the Department of Dermatology of University Federico II of Naples (Italy). The mean duration of dupilumab treatment was 27.31 ± 21.26 months. A total of 148 of 916 (16.15%) (90 males; mean age, 50.91 ± 15.34 years) patients reported other cAEs apart of AD flare; namely, facial redness (82 of 916; 8.95%), psoriasis (39 of 916; 4.25%), alopecia areata (11 of 916; 1.2%), skin peeling (11 of 916; 1.2%), parapsoriasis (three of 916; 0.32%), and vitiligo (two of 916; 0.21%). Thirty-one of 916 (3.38%) patients discontinued dupilumab because of cAEs (18 of 916; 1.96%) for facial redness, 10 of 916 (1.09%) for psoriasis, and three of 916 (0.32%) for parapsoriasis. In our population, most of the cAEs were mild and did not require discontinuation of dupilumab. These findings would enable dermatologists understand the cutaneous side effects of dupilumab better, resulting in improved treatment plan decisions in clinical practice.
    MeSH term(s) Male ; Female ; Adolescent ; Child ; Humans ; Adult ; Middle Aged ; Aged ; Dermatitis, Atopic/drug therapy ; Retrospective Studies ; Treatment Outcome ; Severity of Illness Index ; Psoriasis ; Alopecia Areata ; Parapsoriasis
    Chemical Substances dupilumab (420K487FSG)
    Language English
    Publishing date 2023-03-13
    Publishing country England
    Document type Journal Article
    ZDB-ID 800103-0
    ISSN 1346-8138 ; 0385-2407
    ISSN (online) 1346-8138
    ISSN 0385-2407
    DOI 10.1111/1346-8138.16764
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.B 1950: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top